2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2018
Impact of a clinical interventions bundle on uptake of HPV vaccine at an OB/GYN clinic
Deshmukh U, Oliveira CR, Griggs S, Coleman E, Avni-Singer L, Pathy S, Shapiro ED, Sheth SS. Impact of a clinical interventions bundle on uptake of HPV vaccine at an OB/GYN clinic. Vaccine 2018, 36: 3599-3605. PMID: 29759380, PMCID: PMC6314176, DOI: 10.1016/j.vaccine.2018.05.039.Peer-Reviewed Original ResearchConceptsIntervention bundleOB/GYN clinicPrevalence of womenUninsured womenVaccine uptakeAttributable reductionsMissed opportunityHPV vaccine seriesVaccine-eligible visitsVaccine-eligible womenHPV vaccine uptakeMonthly rateYoung adult womenLast study monthInterrupted time series modelHPV vaccineVaccine seriesMedical recordsHispanic womenAdult womenWhite womenStudy periodYoung adultsVaccineWomen